Thymulin: The Thymus Hormone That Needs Zinc

The short version

Thymulin is a nine-amino-acid peptide (a nonapeptide) produced exclusively by the epithelial cells of the thymus — the gland behind the breastbone that teaches immune cells who they are. Its sequence is pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, and it has one unusual requirement: it is biologically inactive unless it binds a single zinc ion in a 1:1 ratio. Only the zinc-bound form (Zn-thymulin) exerts its documented effects on T-lymphocyte differentiation ^[12].

The peptide is also known as serum thymic factor (FTS, from the French facteur thymique serique). Its production by the thymus is regulated by the neuroendocrine system, and thymulin itself acts back on the pituitary — a bidirectional loop that connects immune and hormonal function ^[11]. Most evidence is preclinical. Thymulin is not approved for human use, and this page gives no dose or clinical guidance.

What it is

Thymulin is a linear nonapeptide with the sequence pyroGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (written abbreviated as <Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), molecular formula C33H54N12O15. The N-terminal glutamic acid exists in a cyclized, pyroglutamate form. Biological activity depends on one zinc(II) ion bound per molecule in an equimolecular ratio; the zinc-bound form adopts a specific three-dimensional conformation, detectable by NMR, that the apo-peptide (zinc-free form) cannot form. Serum thymulin activity falls with zinc deficiency in both animals and humans, and is corrected by zinc supplementation — making it a sensitive biochemical indicator of zinc status ^[12].

Thymulin is also known under the synonym FTS (facteur thymique serique) and by the designation Zn-thymulin when the zinc-bound form is specifically referenced. It is produced only by thymic epithelial cells and is not made by any other tissue ^[9]. The closely related synthetic analog nonathymulin (or metFTS) has been used in gene-therapy research. Do not conflate thymulin with thymosin alpha-1 (Zadaxin), thymosin beta-4 (TB-500), thymopentin, or thymalin (a bovine thymic complex) — these are chemically and pharmacologically distinct compounds ^[11].

How it works

Thymulin drives T-lymphocyte differentiation: it acts on immature T-cells to promote their maturation into functional T-cell subsets capable of mounting immune responses. This is its canonical role in thymic physiology ^[9].

Beyond T-cell biology, thymulin functions as a hypophysiotropic peptide — it acts on anterior pituitary cells, stimulating ACTH release, while its own production by the thymus is in turn regulated by growth hormone, prolactin, and other pituitary-origin signals. This creates a bidirectional thymus-neuroendocrine axis with potential relevance to aging, where thymus involution reduces circulating thymulin and alters hormonal and reproductive regulation ^[9][11].

At the cell-signaling level, thymulin exerts anti-inflammatory effects partly through NF-kB suppression and modulation of SAPK/JNK pathways, paralleling — though independently of — KPV's mechanism. In mouse models of LPS-induced systemic inflammation, thymulin lowered pro-inflammatory cytokines and heat-shock proteins via these pathways ^[10]. It also appears to exert anti-inflammatory and analgesic actions in the brain when delivered directly, with durable expression demonstrated from adenoviral gene-therapy vectors injected into rat brain ^[11].

What the research shows

Asthma gene therapy. A 2020 study in mice with fully established experimental allergic asthma demonstrated near-complete therapeutic reversal of key lung pathologies — chronic inflammation, pulmonary fibrosis, and mechanical dysregulation — 20 days after a single intratracheal dose of mucus-penetrating nanoparticles delivering thymulin-expressing plasmids ^[8]. The reversal worked via anti-inflammatory and antifibrotic mechanisms, and the model represented fully established (not prevented) disease.

Physiology and gene-therapy review. A 2014 review of thymulin's physiology and therapeutic potential documents production exclusively by thymic epithelial cells, neuroendocrine regulation of that production, and the use of a synthetic biologically active analog (metFTS) cloned into regulatable adenovectors that restored circulating thymulin and prevented hormonal and reproductive abnormalities in congenitally athymic mice used as a neuroendocrine aging model ^[9].

LPS-induced inflammation model. In male BALB/c mice given daily thymulin for two weeks before LPS challenge, anti-inflammatory effects were comparable to dietary fat-soluble antioxidants: plasma pro-inflammatory cytokines, inducible HSP72 and HSP90alpha were lower, NF-kB/SAPK/JNK signaling was dampened, and TLR4 expression modulated. Thymulin also enhanced the effect of an IKK inhibitor in preventing IKK activation ^[10].

Thymus-neuroendocrine axis and CNS role. A 2009 review established the bidirectional thymus-neuroendocrine axis: neuroendocrine hormones regulate thymulin secretion, and thymulin itself acts as a hypophysiotropic peptide on the anterior pituitary. The review also documents thymulin's anti-inflammatory and analgesic activity in the brain and durable expression from adenoviral thymulin gene-therapy vectors injected into rat brain ^[11].

Zinc-dependence and identity. The foundational biochemical study established thymulin's nonapeptide sequence, the equimolecular zinc-binding requirement, and the zinc-conformation dependence; it also demonstrated that serum thymulin activity falls with zinc deficiency and is corrected by zinc supplementation in both animals and humans ^[12].

Reported effects, cautions & safety

There are no real-world community-use reports or published human clinical trials for thymulin compiled in this desk's source material. The points below come from the preclinical and review record.

Several cautions follow directly from the literature:

• Not FDA-approved for any human use. Thymulin is a research peptide handled as a laboratory research chemical only; no drug application or supplement registration exists in any major jurisdiction ^[9].
• Human clinical data are sparse. Most evidence is from cell and animal models. Some published studies used the synthetic analog nonathymulin rather than native thymulin itself, and their results may not directly transfer ^[9].
• Activity is strictly zinc-dependent. Thymulin is biologically inactive without one bound zinc ion per molecule. Reported biological effects are therefore always entangled with the zinc status of the experimental system, complicating interpretation of thymulin-specific outcomes independent of zinc ^[12].
• Conflation risk. Consumer and research sources frequently conflate thymulin with thymosin alpha-1, thymosin beta-4 (TB-500), thymopentin, and thymalin (a bovine thymic complex). These are chemically and pharmacologically distinct; claims from one should not be attributed to another ^[11].
• Pharmacokinetics and human dosing. Standardized human dosing and pharmacokinetics (including half-life in humans) are not well characterized in the public literature.
• Preliminary specific claims. Claims derived from small single-author studies — such as specific hair-regrowth percentages from a topical zinc-thymulin pilot — represent early, unconfirmed results and should be treated as preliminary.

Where it fits in immune research

On this desk, Thymulin occupies the central immune role: while KPV quiets peripheral inflammation at a tissue site, thymulin governs the upstream programming of T-lymphocytes in the thymus and ties the immune system to neuroendocrine regulation ^[9][11]. Its gene-therapy applications represent an emerging and distinct use case — restoring a thymic signal that naturally declines with age or thymic insufficiency. Thymulin completes the desk's two-sided view of immune modulation: peripheral cytokine quieting versus central lymphocyte programming. See the comparison page for how they line up.